Rethinking the treatment of chronic fatigue syndrome-a reanalysis and evaluation of findings from a recent major trial of graded exercise and CBT. — CFSMEATLAS
Rethinking the treatment of chronic fatigue syndrome-a reanalysis and evaluation of findings from a recent major trial of graded exercise and CBT.
Wilshire, Carolyn E, Kindlon, Tom, Courtney, Robert et al. · BMC psychology · 2018 · DOI
Quick Summary
This study re-examined a large, well-known trial called PACE that tested whether exercise therapy and talking therapy could help people with ME/CFS. When researchers checked the original study data using the methods that were promised before the trial started, they found much weaker benefits than originally reported. The treatments did not clearly work better than standard care, recovery rates were very low, and improvements seemed to fade after two years.
Why It Matters
This reanalysis is crucial because the original PACE trial conclusions influenced clinical guidelines recommending GET and CBT for ME/CFS worldwide. This critical re-examination reveals that the evidence base for these treatments may be substantially weaker than previously believed, which has significant implications for treatment recommendations and patient care decisions.
Observed Findings
Treatment groups did not significantly outperform controls on primary outcomes after applying multiple comparison corrections
Recovery rates remained consistently low and were not significantly different between treatment and control groups
Significant treatment effects were almost entirely limited to self-report measures rather than objective measures
Observed improvements did not persist beyond the two-year follow-up period
Findings suggest effects may be explained by participant reporting biases rather than genuine clinical improvement
Inferred Conclusions
The original PACE trial conclusions regarding moderate efficacy of CBT and GET are not fully justified when analyses follow protocol-specified procedures
The modest treatment effects observed on self-report measures are consistent with placebo or reporting bias effects rather than true therapeutic benefit
The robustness of claims about CBT and GET efficacy for ME/CFS should be reconsidered in light of protocol-adherent reanalysis
Remaining Questions
What objective biomarkers or measures could be used to assess ME/CFS treatment outcomes independent of patient self-report bias?
What alternative or complementary treatments should be investigated for ME/CFS if GET and CBT are not as effective as previously claimed?
What This Study Does Not Prove
This reanalysis does not prove that GET and CBT are completely ineffective for all ME/CFS patients. It does not establish what treatments would be more effective, nor does it explain the mechanisms of ME/CFS itself. The study relies on reanalysis of existing data rather than new experimental evidence.
Why did the original PACE trial analyses deviate from the pre-specified protocol, and what can be done to prevent such discrepancies in future research?
What is the mechanism of any observed self-report improvements, and do they translate to meaningful functional benefit for patients?